Table 2.
Correlations of clinic-pathologic characteristics with 9p24.1 alteration in HCC patients from training cohort (n = 240) and validation cohort (n = 258).
| Training cohort | Validation cohort | |||||
|---|---|---|---|---|---|---|
| Characteristics | With alteration | Without alteration | P* | With alteration | Without alteration | P* |
| Age, years | ||||||
| ≤51 | 33 | 60 | 0.844 | 38 | 93 | 0.152 |
| > 51 | 54 | 93 | 27 | 100 | ||
| Gender | ||||||
| Female | 16 | 32 | 0.638 | 7 | 31 | 0.297 |
| Male | 71 | 121 | 58 | 162 | ||
| HBsAg | ||||||
| Negative | 4 | 14 | 0.307† | 4 | 5 | 0.236† |
| Positive | 83 | 139 | 61 | 188 | ||
| HBcAb | ||||||
| Negative | 16 | 18 | 0.157 | 4 | 5 | 0.236† |
| Positive | 71 | 135 | 61 | 188 | ||
| AFP (ng/ml) | ||||||
| ≤20 | 36 | 55 | 0.404 | 27 | 72 | 0.544 |
| >20 | 51 | 98 | 38 | 121 | ||
| ALT (U/L) | ||||||
| ≤75 | 70 | 132 | 0.235 | 57 | 169 | 0.976 |
| >75 | 17 | 21 | 8 | 24 | ||
| γ-GT (U/L) | ||||||
| ≤54 | 35 | 89 | 0.007 | 15 | 36 | 0.438 |
| >54 | 52 | 64 | 50 | 157 | ||
| Liver cirrhosis | ||||||
| No | 13 | 25 | 0.776 | 8 | 23 | 0.933 |
| Yes | 74 | 128 | 57 | 170 | ||
| Tumor size (cm) | ||||||
| ≤5 | 41 | 98 | 0.011 | 21 | 96 | 0.015 |
| >5 | 46 | 55 | 44 | 97 | ||
| Tumor number | ||||||
| Single | 64 | 120 | 0.391 | 52 | 156 | 0.884 |
| Multiple | 23 | 33 | 13 | 37 | ||
| Vascular invasion | ||||||
| No | 53 | 100 | 0.491 | 32 | 131 | 0.007 |
| Yes | 34 | 53 | 33 | 62 | ||
| Tumor encapsulation | ||||||
| None | 38 | 56 | 0.280 | 24 | 86 | 0.282 |
| Complete | 49 | 97 | 41 | 107 | ||
| Tumor differentiation | ||||||
| I+II | 55 | 105 | 0.393 | 38 | 138 | 0.051 |
| III+IV | 32 | 48 | 27 | 55 | ||
| TNM stage | ||||||
| I | 72 | 89 | <0.0001 | 43 | 156 | 0.015 |
| II+III | 15 | 64 | 22 | 37 | ||
| BCLC stage | ||||||
| 0-A | 30 | 73 | 0.046 | 14 | 83 | 0.002 |
| B-C | 57 | 80 | 51 | 110 | ||
NOTE: *The Pearson Chi square test was applied. †Chi-square with Yates' correction was applied.
Abbreviations: HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; HBcAb, hepatitis B center antibody; AFP, alpha-fetoprotein; ALT, alanine transaminase; γ-GT, γ-glutamyltransferase; TNM, tumor-node-metastasis; BCLC, Barcelona Clinic Liver Cancer.